论文部分内容阅读
最近美国国立癌症研究所（NCI）向国内肿瘤学家发表了一项声明，推荐三苯氧胺治疗早期乳腺癌的期限为5年。此项声明是继国家外科辅助乳癌、肠癌项目（NSABP）决定停止一项临床试验而发表的。在该试验中，研究人员对淋巴结阴性、雌激素受体阳性的乳腺癌患者术后服用三苯氧胺的期
Recently, the National Cancer Institute (NCI) issued a statement to domestic oncologists recommending tamoxifen for the treatment of early breast cancer for a period of 5 years. The statement was issued after the National Surgical Assistant Breast Cancer and Colorectal Cancer Project (NSABP) decided to stop a clinical trial. In this trial, the researchers performed tamoxifen after surgery for breast cancer patients with negative lymph nodes and positive estrogen receptors.